The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2023 | The importance of targeting TP53 in AML and agents being explored
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, shares some insights into the importance of targeting TP53 in acute myeloid leukemia (AML), and further highlights promising agents and combinations being explored, including eprenetapopt and combinations with magrolimab. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
